SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods. For the moment, it lacks any big wins to point to. Still, innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results